MIR759: A Drug Target / Disease Biomarker (G100313778)
MIR759: A Drug Target / Disease Biomarker
MIR759 is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and kidneys. It is a member of the superfamily of cytoplasmic proteins, which are a type of protein that is found in the cytoplasm of cells.
One of the unique features of MIR759 is its ability to interact with various signaling molecules, including TGF-β1, PDGF, and NF-kappa-B. This suggests that MIR759 may play a role in cell signaling and regulation.
MIR759 has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. It has been shown to interact with proteins such as E-cadherin, which is a protein that is involved in cell-cell adhesion, and vimentin, which is a protein that is involved in cell migration and invasion.
In addition to its role in cell signaling and regulation, MIR759 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that MIR759 is expressed in various types of cancer, and that it is involved in the development of cancer cell invasion and metastasis.
Despite its potential role in disease, MIR759 is not yet a drug target or biomarker. Further research is needed to fully understand the role of MIR759 in cell signaling and regulation, as well as its potential as a drug target or biomarker.
Protein Name: MicroRNA 759
The "MIR759 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR759 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR760 | MIR761 | MIR762 | MIR762HG | MIR764 | MIR765 | MIR766 | MIR767 | MIR769 | MIR770 | MIR7702 | MIR7703 | MIR7704 | MIR7705 | MIR7706 | MIR7843 | MIR7844 | MIR7845 | MIR7846 | MIR7847 | MIR7848 | MIR7849 | MIR7850 | MIR7851 | MIR7854 | MIR7855 | MIR7856 | MIR7974 | MIR7975 | MIR7976 | MIR7977 | MIR802 | MIR8054 | MIR8055 | MIR8059 | MIR8060 | MIR8061 | MIR8063 | MIR8064 | MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942
